Science Business: The Promise, the Reality, and the Future of Biotech

By Gary P. Pisano. 2006

526 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/b7674b508aca511f26e8663d6f7e6248b9ead454

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Rethinking the Commercialization of Public Science: From Entrepreneurial Outcomes to Societal Impacts (2018, background): “…the long-term societal impact rather than micro-level output may help explain and resolve science-to-business tensions driven by the clash of values, norms, and practices between the science and business worlds (Ambos, Mäkelä, Birkinshaw, & D'Este, 2008; Dasgupta & David, 1994; Pisano, 2006).”
Financing Renewable Energy: Who is Financing What and Why it Matters (2018, unknown): “Some studies have examined how short-term speculative financial actors have affected science-based industries (Lazonick and Tulum, 2011; Pisano, 2006).”
Venture Capital as a Catalyst to Commercialization (2010, background): “For example, because of the long time horizons involved in moving through clinical trials, much of the funding for the commercialization of biotechnology products in recent years has come from pharmaceutical companies rather than from venture capital firms (Pisano, 2006).”
Plus ca change: Industrial R&D in the “third industrial revolution” (2008, background): “Pisano (2006) also argues that the IP environment in biotechnology remains filled with uncertainties that have impeded the effectiveness of vertical specialization in biotechnology in both innovation and financial performance.”
The risk-reward nexus in the innovation-inequality relationship: who takes the risks? Who gets the rewards? (2013, background): “…government spending and the business funding that has flowed into the biopharmaceutical industry through private equity (including venture capital), IPOs, secondary stock issues, and R&D contracts, the biopharmaceutical industry has not been productive (Pisano, 2006; Demirel and Mazzucato, 2012).”
Complements or Substitutes? The Role of Universities and Local Context in Supporting the Creation of Academic Spin-offs (2011, unknown): “013 of R&D activities in large firms in different industries has evolved toward more open models as part of which alliances with smaller and more dynamic firms with sophisticated scientific bases, such as academic spin-offs, become a central pillar for the pursuit of new technologies (Pisano, 2006; ”
Organizing Ecologies of Complex Innovation (2011, background): “Many of these technologies remain in the “era of ferment” and do not function well because they are rushed into application (Pisano 2006).”
Networks, Propinquity, and Innovation in Knowledge-intensive Industries (2009, background): “Some recent commentators, however, have contended that scientifi c advance has come at the expense of business success (Pisano, 2006).”
CEO Narcissism, Audience Engagement, and Organizational Adoption of Technological Discontinuities (2013, background): “While traditional pharma R&D is based on chemical synthesis and trial-anderror screening of potential compounds, biotech R&D revolves around the understanding of living organisms, requiring deep expertise in molecular biology (Pisano, 2006).”